Filing Flows › Neogenomics (NEO) › Medicare and other government revenue
Neogenomics (NEO) Medicare and other government revenue by quarter
Neogenomics' Medicare and other government revenue was $29.0M in Q3 2026 (third quarter 2026), +6% from Q2 2026. Over the last 7 quarters it ranged from $21.1M (Q1 2025) to $29.0M (Q3 2026).
| Quarter | Medicare and other government revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $29.0M | +6% | +26% |
| Q2 2026 | $27.4M | +14% | +28% |
| Q1 2026 | $24.1M | -5% | +14% |
| Q4 2025 | $25.4M | +11% | — |
| Q3 2025 | $23.0M | +7% | — |
| Q2 2025 | $21.4M | +1% | — |
| Q1 2025 | $21.1M | — | — |
Q3 2026 at a glance
Neogenomics, Q3 2026: revenue $209M (+11% year over year), operating margin -3.8%, net loss $7.5M, operating cash flow −$8.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neogenomics' Medicare and other government revenue?
Neogenomics' Medicare and other government revenue was $29.0M in Q3 2026 (third quarter 2026), +6% from Q2 2026.
How has Neogenomics' Medicare and other government revenue changed?
Over the last 7 quarters it ranged from $21.1M (Q1 2025) to $29.0M (Q3 2026).